NZ220612A - 11 residue influenza virus peptide and vaccines - Google Patents

11 residue influenza virus peptide and vaccines

Info

Publication number
NZ220612A
NZ220612A NZ220612A NZ22061283A NZ220612A NZ 220612 A NZ220612 A NZ 220612A NZ 220612 A NZ220612 A NZ 220612A NZ 22061283 A NZ22061283 A NZ 22061283A NZ 220612 A NZ220612 A NZ 220612A
Authority
NZ
New Zealand
Prior art keywords
vaccines
residue
influenza virus
virus peptide
peptide
Prior art date
Application number
NZ220612A
Other languages
English (en)
Inventor
N Green
S Alexander
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of NZ220612A publication Critical patent/NZ220612A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ220612A 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines NZ220612A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41045582A 1982-08-23 1982-08-23

Publications (1)

Publication Number Publication Date
NZ220612A true NZ220612A (en) 1988-07-28

Family

ID=23624803

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ220612A NZ220612A (en) 1982-08-23 1983-08-22 11 residue influenza virus peptide and vaccines
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ205341A NZ205341A (en) 1982-08-23 1983-08-22 37 residue influenza virus peptide and vaccines

Country Status (16)

Country Link
EP (1) EP0116629A4 (enrdf_load_stackoverflow)
JP (1) JPS59501714A (enrdf_load_stackoverflow)
KR (1) KR840006198A (enrdf_load_stackoverflow)
AU (1) AU570929B2 (enrdf_load_stackoverflow)
DK (1) DK203684D0 (enrdf_load_stackoverflow)
ES (1) ES525088A0 (enrdf_load_stackoverflow)
FI (1) FI841583L (enrdf_load_stackoverflow)
GR (1) GR78931B (enrdf_load_stackoverflow)
IL (1) IL69556A (enrdf_load_stackoverflow)
IT (1) IT1168636B (enrdf_load_stackoverflow)
NO (1) NO161002C (enrdf_load_stackoverflow)
NZ (2) NZ220612A (enrdf_load_stackoverflow)
PH (1) PH18872A (enrdf_load_stackoverflow)
PT (1) PT77230B (enrdf_load_stackoverflow)
WO (1) WO1984000687A1 (enrdf_load_stackoverflow)
ZA (1) ZA836080B (enrdf_load_stackoverflow)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR241713A1 (es) * 1984-08-30 1992-11-30 Smithkline Beckman Corp Molecula de dna con una secuencia de bases que codifica la proteina c13 y preparacion de vacunas contra la gripe.
US5866363A (en) 1985-08-28 1999-02-02 Pieczenik; George Method and means for sorting and identifying biological information
KR910700259A (ko) * 1989-01-12 1991-03-14 리차드 이. 림바크 T-세포 인지성 펩티드 변형에 의해 면역반응에 영향을 주는 방법
EP0621339B1 (en) * 1992-09-17 2001-10-24 Takara Shuzo Co. Ltd. Immunogenic human influenza A virus haemagglutinin polypeptides
JP2996864B2 (ja) * 1994-03-30 2000-01-11 寳酒造株式会社 抗体可変領域ｄｎａ
US20080014205A1 (en) * 2006-05-15 2008-01-17 Lawrence Horowitz Neutralizing Antibodies to Influenza Viruses
US8148085B2 (en) 2006-05-15 2012-04-03 Sea Lane Biotechnologies, Llc Donor specific antibody libraries
HRP20130163T1 (hr) * 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
ITTO20070066A1 (it) 2007-01-30 2008-07-31 Pomona Biotechnologies Llc Anticorpi monoclonali anti-idiotipo mimotopi dell'antigene gp 120 di hiv
JP5779350B2 (ja) 2007-03-27 2015-09-16 シー レーン バイオテクノロジーズ， エルエルシー 抗体代替軽鎖配列を含む構築物およびライブラリー
ITTO20080204A1 (it) 2008-03-17 2009-09-18 Pomona Biotechnologies Llc Anticorpi monoclonali atti a reagire con una pluralita di sottotipi del virus influenzale a
EP2698380A1 (en) 2008-03-28 2014-02-19 Sea Lane Biotechnologies, LLC Neutralizing molecules to viral antigens
ITTO20080398A1 (it) 2008-05-27 2009-11-28 Pomona Biotechnologies Llc Anticorpi monoclonali aventi proprieta' di cross-neutralizzazione omosubtipica per virus influenzali di tipo a sottotipo h1
ITTO20080964A1 (it) 2008-12-22 2010-06-23 Natimab Therapeutics S R L Anticorpo monoclonale anti-hcv come medicamento per il trattamento terapeutico e la prevenzione di infezioni da hcv
WO2010073647A1 (ja) 2008-12-25 2010-07-01 国立大学法人大阪大学 抗ヒトインフルエンザウイルス・ヒト型抗体
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
WO2010138564A1 (en) 2009-05-26 2010-12-02 Mount Sinai School Of Medicine Of New York University Monoclonal antibodies against influenza virus generated by cyclical administration and uses thereof
IT1395961B1 (it) 2009-06-01 2012-11-02 Pomona Biotechnologies Llc Anticorpi monoclonali come medicamento per il trattamento terapeutico e/o profilattico delle infezioni da virus influenzale a (h1n1) di origine suina (s-oiv)
EP2536425B1 (en) * 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
AU2011235220B2 (en) 2010-03-30 2016-03-10 Mount Sinai School Of Medicine Influenza virus vaccines and uses thereof
US10300140B2 (en) 2011-07-28 2019-05-28 I2 Pharmaceuticals, Inc. Sur-binding proteins against ERBB3
AU2012312529B2 (en) 2011-09-20 2018-01-04 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
EP3446707A1 (en) 2011-12-22 2019-02-27 i2 Pharmaceuticals, Inc. Surrogate binding proteins
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
BR112015014482A2 (pt) 2012-12-18 2017-11-21 Icahn School Med Mount Sinai vacinas para vírus influenza e seus usos
WO2014159960A1 (en) 2013-03-14 2014-10-02 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
AU2016209032A1 (en) 2015-01-23 2017-08-10 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
US10513553B2 (en) 2015-11-13 2019-12-24 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
BR112018075032A2 (pt) 2016-06-15 2019-03-26 Icahn School Of Medicine At Mount Sinai proteínas de hemaglutinina do vírus influenza e seus uso
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
US12364746B2 (en) 2018-06-21 2025-07-22 Icahn School Of Medicine At Mount Sinai Mosaic influenza virus hemagglutinin polypeptides and uses thereof
CN113924147A (zh) 2019-03-25 2022-01-11 威特拉公司 用于治疗和预防流感的组合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI83662C (fi) * 1980-07-17 1991-08-12 Scripps Clinic Res Diagnostik antikropp och foerfarande foer dess framstaellning.

Also Published As

Publication number Publication date
ZA836080B (en) 1984-04-25
DK203684A (da) 1984-04-18
JPS59501714A (ja) 1984-10-11
PT77230B (en) 1986-02-04
PH18872A (en) 1985-10-21
NO841540L (no) 1984-04-17
FI841583A0 (fi) 1984-04-19
IT8348868A1 (it) 1985-02-22
KR840006198A (ko) 1984-11-22
NO161002C (no) 1989-06-21
WO1984000687A1 (en) 1984-03-01
PT77230A (en) 1983-09-01
GR78931B (enrdf_load_stackoverflow) 1984-10-02
EP0116629A1 (en) 1984-08-29
IL69556A (en) 1988-05-31
IL69556A0 (en) 1983-11-30
NO161002B (no) 1989-03-13
AU570929B2 (en) 1988-03-31
NZ205341A (en) 1988-07-28
EP0116629A4 (en) 1987-06-29
DK203684D0 (da) 1984-04-18
ES8505819A1 (es) 1985-06-16
IT8348868A0 (it) 1983-08-22
ES525088A0 (es) 1985-06-16
FI841583A7 (fi) 1984-04-19
IT1168636B (it) 1987-05-20
FI841583L (fi) 1984-04-19
AU1947183A (en) 1984-03-07

Similar Documents

Publication Publication Date Title
NZ220612A (en) 11 residue influenza virus peptide and vaccines
GB2181435B (en) Recombinant lav/htlv virus and vaccines
IL61904A (en) Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
JPS6425800A (en) T-cell epitope of hepatities b virus nucleocapside protein
NZ220365A (en) Antiviral peptides and pharmaceutical compositions
EP0256878A3 (en) Vaccines
GB2212511B (en) Hepatitis c virus
IL80895A0 (en) Material and methods for herpes simplex virus vaccination and diagnosis based on gd-2 glycoprotein
IL64847A (en) Immunomodulating phosphorylsubstituted muramylpeptide analogues and pharmaceutical compositions containing them
AU1255383A (en) Foot and mouth disease viral antigenic peptides
ZA864879B (en) Vaccines and diagnostics derived from boving diarrhoea virus
ZA835014B (en) Avian proventriculitis vaccine
EP0210931A3 (en) Vaccine against varicella-zoster virus
GB2130090B (en) Pharmaceutical preparations and compositions
NZ221374A (en) Recombinant interferon and compositions containing it
HU901571D0 (en) Vaccine and diagnostics against the virus of pig-cholera
IL89118A0 (en) Vaccine containing polypeptides derived from the envelope gene of human immunodeficiency virus type 1
GB8918689D0 (en) 25/15 vaccine
ZA903142B (en) Canine corona virus vaccine
IL79740A0 (en) Hepatitis vaccine
NZ220611A (en) 30 residue influenza virus peptide, vaccines and antibodies
IL65920A (en) Anti-brucellosis vaccine and its preparation
GB2181434A (en) Hepatitis b virus vaccine and process for its preparation
ZA837058B (en) Peptide and use thereof
GB8406901D0 (en) Virus vaccine